SEC For	m 4																				
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549															OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											ΗP	Estim	Numbe ated av	erage burder	3235-0287 0.5	
1. Name and Address of Reporting Person [*] Luthringer Remy					2. Issuer Name and Ticker or Trading Symbol <u>Minerva Neurosciences, Inc.</u> [NERV]										(Cheo X	ck all applica Director	able)	,		ner	
(Last) (First) (Middle) C/O MINERVA NEUROSCIENCES, INC. 1601 TRAPELO ROAD, SUITE 286					3. Date of Earliest Transaction (Month/Day/Year) 10/13/2020										X Officer (give title Other (specif below) below) CEO				респу		
(Street) WALTH	AM M	02451		4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting									
(City) (State) (Zip)															Person						
		Та	ble I - Non	-Deriva	ative	e Se	curities	s Ac	quire	ed, Di	ispose	ed o	of, or Be	enefic	ally	Owned					
				2. Transa Date (Month/D		ar) i	2A. Deemed Execution Date if any (Month/Day/Yea		Code (Inst		on Dis	n Disposed		ties Acquired (A) c I Of (D) (Instr. 3, 4		5. Amoun Securities Beneficia Owned Fo Reported	s For ally (D) following (I)		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Co	ode V	Am	ount	(A) or (D) P		ice	Transacti (Instr. 3 a				insu. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	Transaction Code (Instr.		5. Number Derivativ Securitie Acquired or Dispos of (D) (In 3, 4 and 9	e s I (A) sed str.	6. Date Exercisable ar Expiration Date (Month/Day/Year)			ind	7. Title ar of Securi Underlyir Derivativ (Instr. 3 a	ties ng e Secur		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode V	,	(A)	(D)	Date Exerci	isable	Expirat Date	tion	Title	Amor or Num of Sh	ber		(Instr. 4)				
Employee Stock Option (right to buy)	\$3.5	10/13/2020		A	•		200,000		(1	1)	10/12/2	2030	Common Stock	200,	,000	\$0.00	200,0	00	D		

Explanation of Responses:

1. One-third of this option vests on December 31, 2021 and the balance vests on December 31, 2022.

Remarks:

/s/ Ryan Sansom, Attorney-in-**Fact**

10/14/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.